Protagonist Therapeutics ... (PTGX)
Protagonist Therapeutics Statistics
Share Statistics
Protagonist Therapeutics has 61.38M shares outstanding. The number of shares has increased by 2.27% in one year.
| Shares Outstanding | 61.38M |
| Shares Change (YoY) | 2.27% |
| Shares Change (QoQ) | 1.18% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | 57.88M |
| Failed to Deliver (FTD) Shares | 2.33K |
| FTD / Avg. Volume | 0.24% |
Short Selling Information
The latest short interest is 3.67M, so 6.16% of the outstanding shares have been sold short.
| Short Interest | 3.67M |
| Short % of Shares Out | 6.16% |
| Short % of Float | 6.54% |
| Short Ratio (days to cover) | 5.54 |
Valuation Ratios
The PE ratio is 8.64 and the forward PE ratio is -47.74. Protagonist Therapeutics's PEG ratio is -0.02.
| PE Ratio | 8.64 |
| Forward PE | -47.74 |
| PS Ratio | 5.47 |
| Forward PS | 6.4 |
| PB Ratio | 3.52 |
| P/FCF Ratio | 13 |
| PEG Ratio | -0.02 |
Enterprise Valuation
Protagonist Therapeutics Inc. has an Enterprise Value (EV) of 1.12B.
| EV / Earnings | 4.06 |
| EV / Sales | 2.57 |
| EV / EBITDA | 4.41 |
| EV / EBIT | 4.41 |
| EV / FCF | 6.11 |
Financial Position
The company has a current ratio of 12.48, with a Debt / Equity ratio of 0.02.
| Current Ratio | 12.48 |
| Quick Ratio | 12.48 |
| Debt / Equity | 0.02 |
| Total Debt / Capitalization | 1.58 |
| Cash Flow / Debt | 16.95 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is 0.41% and return on capital (ROIC) is 36.29%.
| Return on Equity (ROE) | 0.41% |
| Return on Assets (ROA) | 0.37% |
| Return on Capital (ROIC) | 36.29% |
| Revenue Per Employee | $3,447,880.95 |
| Profits Per Employee | $2,184,031.75 |
| Employee Count | 126 |
| Asset Turnover | 0.58 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 4.22M |
| Effective Tax Rate | 0.02 |
Stock Price Statistics
The stock price has increased by 70.96% in the last 52 weeks. The beta is 2.33, so Protagonist Therapeutics's price volatility has been higher than the market average.
| Beta | 2.33 |
| 52-Week Price Change | 70.96% |
| 50-Day Moving Average | 42.28 |
| 200-Day Moving Average | 41.26 |
| Relative Strength Index (RSI) | 54.58 |
| Average Volume (20 Days) | 965.39K |
Income Statement
In the last 12 months, Protagonist Therapeutics had revenue of 434.43M and earned 275.19M in profits. Earnings per share was 4.47.
| Revenue | 434.43M |
| Gross Profit | 434.43M |
| Operating Income | 252.84M |
| Net Income | 275.19M |
| EBITDA | 252.84M |
| EBIT | 252.84M |
| Earnings Per Share (EPS) | 4.47 |
Balance Sheet
The company has 97.25M in cash and 10.87M in debt, giving a net cash position of 86.38M.
| Cash & Cash Equivalents | 97.25M |
| Total Debt | 10.87M |
| Net Cash | 86.38M |
| Retained Earnings | -340.52M |
| Total Assets | 744.73M |
| Working Capital | 544.24M |
Cash Flow
In the last 12 months, operating cash flow was 184.15M and capital expenditures -1.35M, giving a free cash flow of 182.8M.
| Operating Cash Flow | 184.15M |
| Capital Expenditures | -1.35M |
| Free Cash Flow | 182.8M |
| FCF Per Share | 2.97 |
Margins
Gross margin is 100%, with operating and profit margins of 58.2% and 63.34%.
| Gross Margin | 100% |
| Operating Margin | 58.2% |
| Pretax Margin | 64.32% |
| Profit Margin | 63.34% |
| EBITDA Margin | 58.2% |
| EBIT Margin | 58.2% |
| FCF Margin | 42.08% |
Dividends & Yields
PTGX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 9.04% |
| FCF Yield | 6.02% |
Analyst Forecast
The average price target for PTGX is $61, which is 23.3% higher than the current price. The consensus rating is "Buy".
| Price Target | $61 |
| Price Target Difference | 23.3% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
Scores
| Altman Z-Score | 29.33 |
| Piotroski F-Score | 5 |